" /> Cancer ‘vaccine’ shows promise in human trial of lymphoma patients
Select Page

An experimental cancer “vaccine” showed promising results in a small clinical trial of patients with lymphoma, according to a study published Monday in the journal Nature Medicine.

Researchers at New York’s Mount Sinai Hospital tested the treatment in 11 patients with lymphoma. Their results were successful enough to warrant another clinical trial in March on lymphoma patients as well as breast and head-and-neck cancer.

Researchers said some patients in the initial human trial went into full remission for months or even years.

The treatment “has broad implications for multiple types of cancer,” said lead author, Dr. Joshua Brody, director of the lymphoma immunotherapy program. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”

They refer to it as a vaccine because it causes a person’s immune system to fight the disease, though it’s not preventive like the flu shot. In this case, the treatment teaches the body to recognize tumors and attack them.

Researchers created the treatment directly inside the tumor. To do this, they injected one tumor with a stimulant to recruit immune cells, treated the tumor with a low dose of radiation then injected it with a stimulant to activate immune cells. These activated immune cells then travel throughout the body, killing tumors wherever they find them.

In three of the patients, the treatment shrunk not only the tumor that was treated but also other ones throughout the body, putting these patients into remission.

“It’s really promising, and the fact you get not only responses in treated areas, but areas outside the field [of treatment with radiation] is really significant,” said Dr. Silvia Formenti, chairwoman of radiation oncology at Weill Cornell Medicine and NewYork-Presbyterian, who was not involved in the study and is working on a similar treatment. Read more

Also Read: Brain zaps boost memory in people over 60, study finds